Arvinas Reports Q2 Profitability Driven by VEPPANU Licensing & Milestone Payments, Extends Cash Runway to H2 2028
ARVN sits 49% above its 52-week low of $6.055 on elevated volume (3.7× avg).
Summary
Arvinas reported a strong Q2 2026, achieving profitability with $249.7M in revenue and $169.4M in net income, driven by its VEPPANU licensing deal and related milestone payments. The company also extended its cash runway into the second half of 2028.
Key Events · Earnings and Guidance · ARVN
-
Significant Financial Turnaround
Reported Q2 2026 revenue of $249.7 million, a substantial increase from $22.4 million in Q2 2025. The company achieved a net income of $169.4 million in Q2 2026, a significant improvement from a net loss of $61.2 million in Q2 2025.
-
VEPPANU Global Licensing Deal
Entered a global licensing agreement with Rigel Pharmaceuticals for its FDA-approved drug VEPPANU, receiving a $70.0 million upfront payment (shared with Pfizer) and an additional $15.0 million for transition activities. Arvinas is also eligible for up to $320.0 million in future development, regulatory, and commercial milestones, plus tiered royalties.
-
Pfizer Milestone Payment
Received a $50.0 million development milestone payment from Pfizer Inc. in connection with VEPPANU's FDA approval.
-
Extended Cash Runway
Cash, cash equivalents, and marketable securities totaled $567.9 million as of June 30, 2026, which is expected to fund operations into the second half of 2028.
Analysis · ARVN · Life Sciences
Arvinas has reported a significant financial turnaround in Q2 2026, moving from a substantial net loss to considerable net income. This positive shift is primarily due to the global licensing agreement for its FDA-approved drug VEPPANU, which generated significant upfront and milestone payments. The company also provided an updated cash runway, indicating sufficient funds to support operations into the second half of 2028, a critical factor for a biotechnology firm. While there are ongoing pipeline developments and some clinical holds, the immediate financial strength and strategic partnership for VEPPANU are highly impactful.
At the time of this filing, ARVN was trading at $9.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $580.7M. The 52-week trading range was $6.06 to $14.51. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.